BDBM108108 US8598206, 117::US8598206, 123

SMILES N=C(N)c4ccc(CNC(=O)[C@H](CCC1CCNCC1)NC(=O)[C@@H](CCCc2cc[n+]([O-])cc2)NS(=O)(=O)Cc3ccccc3)cc4

InChI Key InChIKey=BVZHCUOVJATBQP-UHFFFAOYSA-N

Data  21 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 21 hits for monomerid = 108108   

TargetPlasminogen(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetPlasminogen(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  4nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  4nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  400nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  400nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetVitamin K-dependent protein C(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  850nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetVitamin K-dependent protein C(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  850nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  870nMAssay Description:Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  870nMAssay Description:Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  1.40E+3nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  1.40E+3nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  2.40E+3nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  2.40E+3nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetTranscription initiation factor IIA subunit 1(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  4.90E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetTranscription initiation factor IIA subunit 1(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  4.90E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetComplement C1s subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  9.50E+3nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetComplement C1s subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi:  1.00E+4nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetComplement C1r subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetComplement C1r subcomponent(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 123 | US8598206, 117)
Affinity DataKi: >2.00E+5nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/28/2014
Entry Details
Go to US Patent